Clinical Trials Browser

Recruiting × Leukemia, Myeloid, Acute × Mesna × Clear all

Leukemia, Myeloid, Acute

NCT05436418 2026-03-20

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1/2 Recruiting

260 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Phase 1/2 Recruiting

12 enrolled

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06326463 2026-01-23

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Phase 1 Recruiting

18 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04678401 2025-10-20

IS-free Treg HaploHCT

Phase 1 Recruiting

30 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

CertainT-1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

IS-free Treg HaploHCT